3 registrations that name chromium as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT07402382
Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri/Post-Menopausal Women
No phase
Nutrition 21, Inc.
About 60 people
Started Nov 1, 2025
In plain words A study of chromium in female participants 40 to 70, run by Nutrition 21, Inc.. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 40 to 70; healthy volunteers accepted. Conditions: Glucose Monitoring, Continuous; Whole Body Protein Metabolism; Peri-menopausal Women; Post-menopause.
≥ 60 days but < 12 months of amenorrhea (late perimenopause)
Women with ≥ 12 months of spontaneous amenorrhea (post-menopausal)
No more than 3 days per week of structured physical activity
Provide voluntary signed and dated informed consent.
11 more inclusion criteria and the exclusion criteria are on the listing.
The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic control over a 24-hour period. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06860087
Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Patients with Gestational Diabetes
Phase 1 and 2
University of Kasdi Merbah
About 200 people
Starts May 2025 (estimated)
In plain words A Phase 1 and 2 study of chromium in female participants of any age, run by University of Kasdi Merbah. It plans to enroll about 200 people at 1 site, none in the US.
They have no pathology or complication associated with their pregnancy.
Pregnant women with gestational diabetes mellitus:
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (200 µg/d); Dietary Supplement: Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (400 µg/d)
Registered summary
Our study aims to explore the influence of dietary chromium supplementation in the form of chromium picolinate, at different doses (200 µg and 400 µg per day), on the health of pregnant women with gestational diabetes. This study will also provide more information on the safety of this type of supplementation during pregnancies complicated by gestational diabetes mellitus. The full summary is on the listing.
Where, as registered
No US site; Algeria (1).
Not yet recruitingNCT07703358
Effect of Chromium Weight Reduction on Adult Asthma Control
No phase
Cairo University
About 60 people
Starts Aug 20, 2026 (estimated)
In plain words A study of chromium in people 18 to 65, run by Cairo University. It plans to enroll about 60 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Asthma Chronic; Bronchial Asthma.
Age: 18-65 years
Confirmed asthma diagnosis according to GINA criteria (7)
Asthma stable for at least 4 weeks (no acute exacerbation)
BMI of 30 kg/m² (obese category)
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Chromium picolinate
Registered summary
This phase IV randomized controlled trial is designed to evaluate the effects of chromium picolinate supplementation in obese adults with stable asthma. A total of 60 participants will be recruited from Ain Shams University Hospitals and randomly assigned to receive either 400 mcg of chromium picolinate daily or a matching placebo for 12 weeks, in addition to standard asthma therapy. The study aims to explore the interaction between metabolic dysfunction and asthma, as obesity-related asthma is often associated with systemic inflammation, insulin resistance, and dyslipidemia. The full summary is on the listing.